Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 2022

View Archived Issues

NF1 mutation impacts neurons to modify tumor predisposition by increasing neuronal excitability

Arvinas Operations describes PROTACs for androgen receptor degradation

New tachykinin NK2 receptor agonists identified at Embark Biotech

New IL-17 modulators discovered at UCB

Zydus Lifesciences patents bacterial dihydrofolate reductase inhibitors

Betta Pharmaceuticals describes histone acetyltransferase KAT3B inhibitors

Artemisinin derivatives as potential agents for the treatment of MS

Anti-NOTCH3 treatment reverses experimental pulmonary arterial hypertension

Cat model of Rdh5-associated retinopathy mimics the human phenotype

Close look illuminates ketamine's (relative) staying power

Olverembatinib, ponatinib identified as possible treatments for COVID-related cytokine storm

SRSF9 overexpression correlates with CRC lymph node metastasis and Dukes stage

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...